Association of current molecular subtypes in urothelial carcinoma with patterns of muscularis propria invasion

被引:11
|
作者
Haghayeghi, Koorosh [1 ,2 ]
Lu, Shaolei [1 ,2 ]
Matoso, Andres [3 ]
Schiff, Stephen F. [4 ]
Mueller-Leonhard, Catrina [5 ,6 ,7 ]
Amin, Ali [1 ,2 ,8 ]
机构
[1] Brown Univ, Warren Alpert Med Sch, Rhode Isl Hosp, Dept Pathol & Lab Med, Providence, RI 02903 USA
[2] Brown Univ, Warren Alpert Med Sch, Lifespan Med Ctr, Providence, RI 02903 USA
[3] Johns Hopkins Univ Hosp, Dept Pathol & Lab Med, Baltimore, MD 21287 USA
[4] Brown Urol, 195 Collyer St,Ste 201, Providence, RI 02904 USA
[5] Miriam Hosp, Dept Oncol, Providence, RI 02903 USA
[6] Miriam Hosp, Minimally Invas Urol Inst MIUI, Providence, RI 02903 USA
[7] Lifespan Med Ctr, Providence, RI 02903 USA
[8] Miriam Hosp, Dept Pathol & Lab Med, 164 Summit Ave, Providence, RI 02906 USA
关键词
Urothelial carcinoma; Molecular subtypes; Basal; Luminal; Muscle invasive bladder cancer; BLADDER-CANCER; RADICAL CYSTECTOMY; IDENTIFICATION; GROWTH; BASAL;
D O I
10.1007/s00428-021-03145-y
中图分类号
R36 [病理学];
学科分类号
100104 ;
摘要
Urothelial carcinoma is subdivided into luminal (L), basal (B), and p53-wild-type (WT) molecular subtypes, with basal and p53-WT groups showing more aggressive course and poor treatment response, respectively. The literature on molecular subtypes of UC includes a mixture of different stages. We investigated the molecular profile and outcome of pure cohort of muscle invasive bladder carcinoma (MIBC) considering two distinct patterns of muscularis propria (MP) invasion. Forty-three cystectomies harboring stage pT2 were retrospectively identified in 18 years. MP invasion was subclassified into patterns 1 (tumor encasing intact detrusor muscle bundles) and 2 (tumor dissecting/replacing detrusor muscle). Using IHC, B/L phenotypes, p53, and Ki67 were assessed, and survival data was collected. Pattern 1 invasion was noted in 16 (37%) and pattern 2 in 27 (63%), with mean age of pattern 1 being 10 years younger. B/L phenotypes were successfully determined in 83.7%; 48.8% and 34.8% revealed L and B phenotypes, respectively (indeterminate phenotype in 16.4%). Pattern 1 was associated with L phenotype (GATA3 and HER-2 expressions: p = 0.02 & p = 0.04, respectively). Ki67 >= 5/10HPF was noted in pattern 2 and B phenotype (p = 0.03). B phenotype showed association with p53-WT (p = 0.007). In median follow-up of 60.7 months, 63.6% of pattern 1 cases were alive without disease compared to 32% of pattern 2 (not significant). A panel of CK20 and GATA3 for luminal and CK5/6 and CK14 for basal subtypes can provide reliable molecular classification in UC. Also, morphology of MIBC can predict the molecular phenotype and the behavior of the UC.
引用
收藏
页码:515 / 521
页数:7
相关论文
共 48 条
  • [22] Urothelial transitional cell carcinoma with endophytic growth patterns - A discussion of patterns of invasion and problems associated with assessment of invasion in 18 cases
    Amin, MB
    Gomez, JA
    Young, RH
    AMERICAN JOURNAL OF SURGICAL PATHOLOGY, 1997, 21 (09) : 1057 - 1068
  • [23] The aggressiveness of urothelial carcinoma depends to a large extent on lymphovascular invasion - the prognostic contribution of related molecular markers
    Afonso, Julieta
    Santos, Lucio Lara
    Amaro, Teresina
    Lobo, Francisco
    Longatto-Filho, Adhemar
    HISTOPATHOLOGY, 2009, 55 (05) : 514 - 524
  • [24] Patterns of invasion and histological growth as prognostic indicators in urothelial carcinoma of the upper urinary tract
    Langner, C
    Hutterer, G
    Chromecki, T
    Rehak, P
    Zigeuner, R
    VIRCHOWS ARCHIV, 2006, 448 (05) : 604 - 611
  • [25] TROP2 Expression Across Molecular Subtypes of Urothelial Carcinoma and Enfortumab Vedotin-resistant Cells
    Chou, Jonathan
    Trepka, Kai
    Sjostrom, Martin
    Egusa, Emily A.
    Chu, Carissa E.
    Zhu, Jun
    Chan, Emily
    Gibb, Ewan A.
    Badura, Michelle L.
    Contreras-Sanz, Alberto
    Stohr, Bradley A.
    Meng, Maxwell, V
    Pruthi, Raj S.
    Lotan, Yair
    Black, Peter C.
    Porten, Sima P.
    Koshkin, Vadim S.
    Friedlander, Terence W.
    Feng, Felix Y.
    EUROPEAN UROLOGY ONCOLOGY, 2022, 5 (06): : 714 - 718
  • [26] Utility of p63 and high molecular weight cytokeratin in the distinction between urothelial carcinoma with prostatic stromal invasion and urothelial carcinoma with colonisation of prostatic ducts and acini
    Chastain, Elizabeth C.
    Oliva, Irma V.
    Osunkoya, Adeboye O.
    PATHOLOGY, 2012, 44 (03) : 199 - 203
  • [27] Patterns of invasion and histological growth as prognostic indicators in urothelial carcinoma of the upper urinary tract
    C. Langner
    G. Hutterer
    T. Chromecki
    P. Rehak
    R. Zigeuner
    Virchows Archiv, 2006, 448 : 604 - 611
  • [28] Combined Gene Expression and Genomic Profiling Define Two Intrinsic Molecular Subtypes of Urothelial Carcinoma and Gene Signatures for Molecular Grading and Outcome
    Lindgren, David
    Frigyesi, Attila
    Gudjonsson, Sigurdur
    Sjodahl, Gottfrid
    Hallden, Christer
    Chebil, Gunilla
    Veerla, Srinivas
    Ryden, Tobias
    Mansson, Wiking
    Liedberg, Fredrik
    Hoglund, Mattias
    CANCER RESEARCH, 2010, 70 (09) : 3463 - 3472
  • [29] DNA methylation analyses of urothelial carcinoma reveal distinct epigenetic subtypes and an association between gene copy number and methylation status
    Lauss, Martin
    Aine, Mattias
    Sjodahl, Gottfrid
    Veerla, Srinivas
    Patschan, Oliver
    Gudjonsson, Sigurdur
    Chebil, Gunilla
    Lovgren, Kristina
    Ferno, Marten
    Mansson, Wiking
    Liedberg, Fredrik
    Ringner, Markus
    Lindgren, David
    Hoglund, Mattias
    EPIGENETICS, 2012, 7 (08) : 858 - 867
  • [30] Basal and Luminal Molecular Subtypes in Naturally-Occurring Canine Urothelial Carcinoma are Associated with Tumor Immune Signatures and Dog Breed
    Sommer, Breann C.
    Dhawan, Deepika
    Ruple, Audrey
    Ramos-Vara, Jose A.
    Hahn, Noah M.
    Utturkar, Sagar M.
    Ostrander, Elaine A.
    Parker, Heidi G.
    Fulkerson, Christopher M.
    Childress, Michael O.
    Fourez, Lindsey M.
    Enstrom, Alexander W.
    Knapp, Deborah W.
    BLADDER CANCER, 2021, 7 (03) : 317 - 333